Full-Time

Vice President

Multiple Teams

Posted on 9/11/2026

Deadline 9/26/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$274k - $456.6k/yr

+ 30% target bonus + Share-based long-term incentive

No H1B Sponsorship

New York, NY, USA

Hybrid

Work from the New York headquarters 2 to 3 days per week. Domestic travel up to approximately 25%.

Bachelor's, Master's, MBA

Category
Growth & Marketing (1)
Required Skills
Marketing

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 15 years of healthcare-sector experience, including demonstrated success in market access, payer strategy, or brand-level access roles, is required.
  • Deep understanding of the United States healthcare environment, including payer dynamics, formulary mechanics, and gross-to-net economics, is required.
  • Demonstrated experience developing and executing integrated market access plans spanning payer marketing, pricing, and contracting strategy is required.
  • Prior experience in obesity, cardiometabolic, or another high-growth or high-visibility launch category is required.
  • Experience operating in a fast-evolving or newly established category and building strategy and capability without an established playbook is required.
  • Demonstrated business and financial acumen, including understanding brand profit-and-loss dynamics and translating them into access investment and gross-to-net trade-off decisions, is required.
  • Strong influence and negotiation skills, with the ability to build trust and drive alignment with senior business-unit stakeholders, are required.
  • Previous supervisory and people-management experience is required.
  • Demonstrated agility with ambiguity and organizational change is required.
  • Candidates must be authorized to be employed in the United States by any employer.
  • The position requires permanent work authorization in the United States.
Responsibilities
  • Own end-to-end market access strategy for obesity assets from early strategy development through execution, including access strategy, payer marketing, pricing, and contracting in one coherent plan.
  • Define the payer value proposition, messaging, and positioning for obesity assets, tailored to category-specific access barriers and customer dynamics.
  • Set and execute pricing and contracting strategy for obesity assets, balancing access investment against gross-to-net performance to maximize net trade sales.
  • Build and continuously refine the obesity market access playbook as the category, competitive landscape, and payer response evolve.
  • Define and monitor obesity access performance metrics, including access quality, access speed, and gross-to-net performance relative to plan.
  • Serve as the direct partner to the obesity franchise lead within the Primary Care business unit, jointly owning the balance between brand growth objectives and access and gross-to-net discipline.
  • Translate obesity brand profit-and-loss objectives and business goals into access, pricing, and contracting priorities.
  • Flag trade-offs between revenue maximization and gross-to-net discipline to the franchise lead and United States Market Access Primary vice president, ensuring access decisions reflect enterprise-level economics.
  • Represent obesity access needs to United States Market Access Patient and Provider Services leadership and escalate resourcing gaps or strategic misalignment as the category scales.
  • Serve as the single point of accountability for the obesity franchise by coordinating market access and patient services strategies to advance patient, customer, and business outcomes.
  • Partner with Patient Services on the patient journey and jointly shape affordability, hub, adherence, and support strategies so patients can access and remain on therapy.
  • Lead the evolution of obesity patient-support capabilities by identifying category dynamics, direct patient engagement, affordability considerations, and emerging reimbursement pathways requiring innovative models.
  • Own the access portion of the strategic brand plan for obesity pipeline assets and integrate access strategy into brand planning from early lifecycle stages.
  • Build early market-shaping strategy by proactively engaging payers, health systems, and other stakeholders ahead of formulary decisions.
  • Identify and close access-readiness gaps for pipeline obesity assets, including payer coverage, reimbursement pathways, and formulary positioning.
  • Define multi-year market access plans for the obesity pipeline and incorporate gross-to-net inputs into long-range financial planning.
  • Lead and develop a dedicated obesity team, including colleagues covering access marketing strategy and contracting and pricing.
  • Coach team members to operate as strategic owners of their portions of the obesity portfolio.
  • Build the obesity capability and talent pipeline as the category and team scale over time.
  • Participate as a member of the United States Market Access Primary leadership structure and contribute an obesity-specific perspective to broader Primary strategy.
  • Model Pfizer values and leader behaviors.
Desired Qualifications
  • An MBA or advanced degree in a healthcare-related or business field is preferred.
  • Experience partnering directly with brand or franchise leadership on integrated business and access strategy is preferred.
  • Experience with direct-to-patient or direct-to-consumer engagement models is preferred.
  • Familiarity with patient affordability and hub-services program design is preferred.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.